Table 2 |
|||
|
TNF-RI A36G single nucleotide polymorphism genotype frequencies and sTNFR levels |
|||
| Genotype |
n (%) |
sTNF-RI (pg/ml) |
sTNF-RII (pg/ml) |
|
|
|||
| Early RA |
|||
| AA |
41 (39.8) |
1,543 ± 597 |
4,435 ± 1,898 |
| AG |
50 (48.5) |
1,426 ± 629 |
4,302 ± 1,672 |
| GG |
12 (11.7) |
1,303 ± 447 |
4,566 ± 1,490 |
| Established RA |
|||
| AA |
48 (31.8) |
1,827 ± 758 |
5,740 ± 1,942 |
| AG |
70 (46.4) |
1,688 ± 674 |
5,475 ± 2,020 |
| GG |
33 (21.8) |
1,757 ± 559 |
5,857 ± 2,393 |
|
|
|||
|
Shown are tumor necrosis factor receptor I (TNF-RI) A36G single nucleotide polymorphism genotype frequencies and soluble tumor necrosis factor receptor (sTNFR) levels in rheumatoid arthritis (RA) patients with early (n = 103) and established (n = 151) disease. sTNFR levels are expressed as the mean ± standard deviation. No significant differences in sTNFR levels were found between any of the genotypes in either population. sTNF-RII, soluble tumor necrosis factor receptor II. |
|||
|
Glossop et al. Arthritis Research & Therapy 2005 7:R1227 doi:10.1186/ar1816 |
|||
